Home » Stocks » BHC

Bausch Health Companies, Inc. (BHC)

Stock Price: $31.75 USD 0.33 (1.05%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 11.41B
Revenue (ttm) 8.03B
Net Income (ttm) -560.00M
Shares Out 355.00M
EPS (ttm) -5.44
PE Ratio n/a
Forward PE 6.79
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $31.75
Previous Close $31.42
Change ($) 0.33
Change (%) 1.05%
Day's Open 31.90
Day's Range 31.60 - 32.46
Day's Volume 6,049,486
52-Week Range 11.15 - 32.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 3 days ago

Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: ANTM, DD, NSC, TAK, THC
Forbes - 3 days ago

After a solid 2.4x rise from its March 2020 lows, at the current price of $31 per share, Bausch Health Companies' stock, best known for its contact lenses and branded generic drugs, appears to...

PRNewsWire - 3 days ago

LAVAL, QC, Feb. 26, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redempt...

Zacks Investment Research - 4 days ago

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Benzinga - 5 days ago

Bausch Health Companies Inc (NYSE: BHC) is expanding its board of directors to accommodate two designees from activist investor Carl Icahn's Icahn Group, which owns 7.83% of the company's outs...

Zacks Investment Research - 5 days ago

Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 days ago

Shares of Bausch Health Cos (NYSE:BHC) decreased 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 18.75% year over year to $1.33...

PRNewsWire - 5 days ago

Two New Directors to Be Appointed to Board Icahn to Support All Bausch Health Nominees for Election at 2021 Annual Meeting LAVAL, QB, Feb. 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc....

Zacks Investment Research - 6 days ago

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 1 week ago

LAVAL, QC, Feb. 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redempt...

Invezz - 1 week ago

Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company's largest shareho...

Zacks Investment Research - 1 week ago

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 1 week ago

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for...

Benzinga - 1 week ago

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the last five years is 131.9%.

Schaeffers Research - 2 weeks ago

The shares of Bausch Health Companies Inc (NYSE:BHC) are up 4.3% at $31.41 at last check, after Icahn Capital LP reported a 7.8% stake in the pharmaceutical concern, which is the equivalent of...

PRNewsWire - 2 weeks ago

LAVAL, QC, Feb. 11, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") issued the following statement in response to the Schedule 13D filed by...

GlobeNewsWire - 3 weeks ago

Nicox Investors & Media Contact: Gavin Spencer communications@nicox.com +33 (0)4 97 24 53 00 Mary-Ann Chang mchang@lifesciadvisors.com +44 7483 284 853 Nicox Media France Contact: Sophie Baumo...

PRNewsWire - 1 month ago

LAVAL, Quebec, Jan. 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2020 financial results on Wednesday, F...

Zacks Investment Research - 1 month ago

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

PRNewsWire - 1 month ago

Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients LAVAL, QC, Jan. 20, 2021 /PRNewswire/ -- Bausch + Lom...

The Motley Fool - 1 month ago

The healthcare company released a positive preliminary update for the fourth quarter.

Seeking Alpha - 1 month ago

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 39th Annual JP Morgan Healthcare Conference (Transcript)

Other stocks mentioned: JPM
Market Watch - 1 month ago

Bausch Health Corp. shares gained more than 5% in after-hours trading Tuesday after the company announced that its annual revenue will come in higher than its guidance. Bausch Health, formerly...

PRNewsWire - 1 month ago

LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at t...

PRNewsWire - 2 months ago

LAVAL, QC, Dec. 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the Office for Registration of Medicinal Products, Medical Devices...

Market Watch - 2 months ago

Bausch Health Cos. Inc. said Tuesday it is planning to pay down another $275 million of senior secured term loans, using cash on hand and cash generated from operations.

PRNewsWire - 2 months ago

No Debt Maturities or Mandatory Amortization Payments Will Be Due Until 2024 Bausch Health Will Repay Approximately $900 Million of Debt in 2020 LAVAL, QC, Dec. 29, 2020 /PRNewswire/ -- Bausch...

Seeking Alpha - 2 months ago

Bausch Health has performed very poorly so far in 2020, but it has mostly been due to COVID-19 impacts. The pandemic has affected all of their businesses to varying degrees, but the impacts ar...

GuruFocus - 2 months ago

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), positio...

Other stocks mentioned: CHMA, PRTK
Zacks Investment Research - 2 months ago

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 2 months ago

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Other stocks mentioned: RDY, TEVA
Seeking Alpha - 3 months ago

Bausch Health Companies, Inc. (BHC) Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)

Zacks Investment Research - 3 months ago

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

PRNewsWire - 3 months ago

LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announce...

Seeking Alpha - 3 months ago

Bausch Health Companies, Inc. (BHC) Presents at Wolfe Research Healthcare Broker Conference Call - (Transcript)

PRNewsWire - 3 months ago

Following Redemptions, Bausch Health Will Have No Note Maturities Until 2024 LAVAL, QC, Nov. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Comp...

PRNewsWire - 3 months ago

LAVAL, QC, Nov. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined $1.75 bi...

Zacks Investment Research - 3 months ago

Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

Insider Monkey - 3 months ago

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks...

PRNewsWire - 3 months ago

LAVAL, Quebec, Nov. 10, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in two investor c...

Zacks Investment Research - 3 months ago

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Seeking Alpha - 3 months ago

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Bausch (BHC) delivered earnings and revenue surprises of 28.43% and 1.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Market Watch - 3 months ago

Bausch Health Cos. Inc. shares rose 5% in premarket trade Tuesday, after the drug company's better-than-expected revenue offset weaker-than-expected profit.

Seeking Alpha - 3 months ago

The former Valeant Pharmaceuticals has been completely revamped by the new executive team that was faced with a herculean task. After fighting for 4 years to deal with the massive debt load an...

Seeking Alpha - 3 months ago

Investors are discounting the value of the B+L spinoff. Company poised to rebound as surgical procedures resume.

Zacks Investment Research - 3 months ago

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 4 months ago

MELBOURNE, Australia, Oct. 30, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalm...

PRNewsWire - 4 months ago

LAVAL, Quebec, Oct. 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on Nov. 30, 2020 it will redeem (i) approximat...

Zacks Investment Research - 4 months ago

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Other stocks mentioned: EYEN

About BHC

Bausch Health Companies develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and gen... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Joseph C. Papa
Employees
21,700
Stock Exchange
NYSE
Ticker Symbol
BHC
Full Company Profile

Financial Performance

In 2020, BHC's revenue was $8.03 billion, a decrease of -6.67% compared to the previous year's $8.60 billion. Losses were -$560.00 million, -68.68% less than in 2019.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 34.81, which is an increase of 9.64% from the latest price.

Price Target
$34.81
(9.64% upside)
Analyst Consensus: Buy